Other grades of this product :
| BUSERELIN Basic information |
| Product Name: | BUSERELIN | | Synonyms: | (d-ser(bu(supt)(sup6)))-lh-rh(1-9)nonapeptide-ethylamide;(d-ser(tbu)(sup6)-ea(sup10))-lhrh;(d-ser(tbu)(sup6)-ea(sup10))-luteinizinghormone-releasinghormon;(d-ser(tbu)(sup6)-ea(sup10))-luteinizinghormone-releasinghormone;BUSERELIN;1-9-Luteinizing hormone-releasing factor (swine), 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-;Buserilin;BUSERELIN PH. EUR. | | CAS: | 57982-77-1 | | MF: | C60H86N16O13 | | MW: | 1239.42 | | EINECS: | 261-061-9 | | Product Categories: | hormones | | Mol File: | 57982-77-1.mol |
| BUSERELIN Chemical Properties |
| alpha | D20 -40.4° (c = 1 in dimethylacetamide) | | Boiling point | 845.19°C (rough estimate) | | density | 1.0711 (rough estimate) | | refractive index | 1.6200 (estimate) | | solubility | Sparingly soluble in water and in dilute acids. | | pka | 9.82±0.15(Predicted) |
| BUSERELIN Usage And Synthesis |
| Chemical Properties | White or slightly yellowish powder, hygroscopic. | | Uses | Gonad-stimulating principle. | | Brand name | Suprefact
(Hoechst-Roussel). | | Clinical Use | Treatment of advanced prostate cancer and
endometriosis
Pituitary desensitisation in preparation for ovulation
induction regimens using gonadotrophins | | Drug interactions | Potentially hazardous interactions with other drugs
None known | | Metabolism | Metabolic inactivation by peptides occurs in the liver
and kidney. The drug is also inactivated by pituitary
membrane enzymes.
Excreted in the urine and bile as unchanged drug and
metabolites. |
| BUSERELIN Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye